Virtus Health Ltd and Monash IVF Group shares sink on regulatory worries

Regulatory risk is on the table for two of Australia's leading IVF clinics, Virtus Health Ltd (ASX:VRT), and Monash IVF Group Ltd (ASX:MVF).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Regulatory risk is one of the tougher risks to quantify. Even among more experienced investors, time spent listening to the pollies in parliament is time that could usually be spent far more profitably analysing the industry you're investing in.

The latest sector to jump into the regulatory spotlight is the fertility industry, thanks to a rabble-rousing Four Corners episode last night. It looked like a bit of a corporate knife job, but Monash IVF Group Ltd (ASX: MVF) and Virtus Health Ltd (ASX: VRT) were certainly cast in an unflattering light by Four Corners thanks to some interviews with (among others) Michael Chapman, a former director of Virtus Health and president of the Fertility Society of Australia.

In a nutshell, Four Corners argued that a significant number of fertility treatments are ineffective, chances of conception are occasionally misrepresented or glossed over, and government subsidies are helping a number of people (especially the over-40s) who generally have very low chances of conception.

Women over the age of 40 have reportedly been the fastest growing IVF segment over the past decade. Virtus and Monash also attracted extra heat for their focus on cycles rather than live births – in other words profits, not patient outcomes.

Clinics with lower success rates also reportedly chew through greater chunks of money than more successful clinics, yet many customers aren't necessarily aware of the differing success rates between clinics.

What's a shareholder to do?

I'd bet that this issue landed front and centre on a few politicians' tables overnight, but it's an open question if changes will be made to the industry – the recent public backlash over changes to pathology bulk billing was considerable. However, Four Corners reported that Monash, Virtus, and private player Genea account for 80% of the fertility market, meaning that any changes to the sector won't miss these three companies.

It's not too hard to envision an upper limit on patient age or the number of cycles that are covered by government subsidies, which could at the very least impact company growth prospects in the near term. Potential outcomes are both an 'if and when' proposition and highly uncertain, but this is an area that deserves scrutiny by shareholders.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »